Act as a key link between Ultragenyx and the rare disease medical community, providing critical scientific information about our neurology portfolio pipeline and prepare for commercialization of an anti-sense oligonucleotide for the treatment of Angelman syndrome.
$195,600—$241,600 USD; Annual bonus and equity incentives; Not specified
Must-have
Nice-to-have
Not specified